Table 3.
Patient outcomes in the four phase II tipifarnib studies of S0432
| 600 mg bid day 1–21 (n=80) | 600 mg bid d 1–7, 15–21 (n=85) | 300 mg bid day 1–21 (n=82) | 300 mg bid d 1–7, 15–21 (n=84) | ||
|---|---|---|---|---|---|
| CR, CRi, PR | 16% | 12% | 20% | 5% | |
| 95% CI | 9–26% | 6–20% | 12–30% | 1–12% | |
| CR | 8% | 5% | 11% | 1% | |
| CRi | 8% | 6% | 4% | 4% | |
| PR | 1% | 1% | 5% | 0% | |
| Fatal toxicity | 8% | 4% | 2% | 0% | |
| Median survival | 104 days | 116 days | 111 days | 106 days | |
| 12 month overall survival | 13% | 25% | 28% | 15% | |
| 12 month relapse-free survival | 11% | 20% | 17% | 0% |